Clinical Trials Logo

Clinical Trial Summary

This study evaluated the efficacy and safety of aflibercept in the treatment of participants with advanced chemoresistant non-small cell lung adenocarcinoma (NSCLA).

Primary objective:

- To determine the overall objective response rate (ORR) of AVE0005 (ziv-aflibercept, aflibercept, VEGF trap, ZALTRAP®) 4.0 mg/kg intravenously (IV) every 2 weeks in participants with platinum- and erlotinib-resistant, locally advanced or metastatic NSCLA.

Secondary objective:

- To assess duration of response (DR), progression-free survival (PFS), and overall survival (OS) in this participant population

- To evaluate the safety profile of IV AVE0005 (ziv-aflibercept, aflibercept, VEGF trap, ZALTRAP®).

This study employed an Independent Review Committee (IRC) for radiological tumor assessments. For all tumor assessment-related efficacy variables, two analyses were performed: the primary analysis was based on Independent Review Committee (IRC) reviewed data and the secondary analysis was based on Investigator evaluation.

In addition, both Response Evaluation Criteria In Solid Tumors (RECIST) and Modified Response Evaluation Criteria In Solid Tumors (mRECIST) were used to assess tumors. Where as RECIST criteria only consider the longest diameter of the tumors for calculations pertaining to changes in tumor size, mRECIST assessments also account for the differences in the cavities of lesions observed in non-small-cell lung cancer (NSCLC). Responses based on RECIST and mRECIST are reported.


Clinical Trial Description

The study included :

- A screening phase up to 21 days followed by registration

- Treatment initiation within 5 working days of registration

- A treatment phase with 14-day study treatment cycles until a study withdrawal criterion was met or up to the clinical database cut-off date (18 July 2008)

- A follow-up phase - up to 60 days after end of treatment

Withdrawal criteria that led to treatment discontinuation were:

- The participant or their legally authorized representative requested to withdraw

- In the investigator's opinion, continuation of the study would be detrimental to the participant's well being, due to reasons such as disease progression, unacceptable toxicity, noncompliance, or logistical considerations.

- A specific request by the Sponsor

- Participant had intercurrent illness that prevented further administration of study treatment

- Participant had more than 2 aflibercept dose reductions

- Participant had arterial thromboembolic events, including cerebrovascular accidents, myocardial infarctions, transient ischemic attacks, new onset or worsening of pre-existing angina

- Participant had radiographic evidence of intestinal obstruction (e.g., dilated loops of bowel accompanied by air-fluid levels) or gastrointestinal perforation (e.g., presence of extraluminal gas) requiring surgical intervention

- Participant was lost to follow-up

After discontinuing treatment, participants remained on the study until the last post-treatment visit or until recovery of drug related toxicities, whichever was later. ;


Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00284141
Study type Interventional
Source Sanofi
Contact
Status Completed
Phase Phase 2
Start date January 2006
Completion date July 2008

See also
  Status Clinical Trial Phase
Completed NCT01860898 - A Phase I Study of iPS Cell Generation From Patients With COPD N/A
Recruiting NCT04892342 - Study of ESG401 in Adults With Solid Tumors Phase 1/Phase 2
Completed NCT05011890 - Remote Monitoring of Lung Cancer Patient-Reported Outcomes Using Moovcare® N/A
Active, not recruiting NCT00935571 - Incidence of Postthoracotomy Pain Following General Anesthesia: A Comparison Between TIVA and Inhalation Anesthesia N/A
Completed NCT02084823 - Vaccine Therapy in Treating Lung Cancer Patients With Cancer Stem Cells Phase 1/Phase 2
Completed NCT02115958 - The Immunotherapy of Nasopharyngeal Cancer Using Cancer Stem Cells Vaccine Phase 1/Phase 2
Terminated NCT02673021 - MARK 1A Series: Percutaneous Microwave Ablation for Patients With Lung Tumor(s) N/A
Terminated NCT03603652 - NEUWAVE Flex Microwave Ablation System in the Ablation of Primary Soft Tissue Lesions of the Lung N/A
Not yet recruiting NCT01131429 - A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations Phase 2
Completed NCT00042679 - A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer. Phase 2
Not yet recruiting NCT05857995 - Precision Lung Cancer Survivorship Care Intervention N/A
Withdrawn NCT03713099 - NEUWAVE Flexible Probe Study #2 N/A
Recruiting NCT04699188 - Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation Phase 1/Phase 2
Terminated NCT00290017 - Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy Phase 3
Completed NCT02410603 - Isolating and Testing Circulating Tumor DNA and Soluble Immune Markers During the Course of Treatment for Lung Cancer
Recruiting NCT02549638 - Identification of Prognostic Biomarkers for Progression of Invasive Squamous Cell Carcinoma
Completed NCT02370303 - A Study to Isolate and Test Circulating Tumor Cells Using the ClearCell® FX EP+ System